Exact Sciences had its Relative Strength (RS) Rating upgraded from 68 to 72 Wednesday — a welcome improvement, but still below the 80 or better score you prefer to see.
When To Sell Stocks To Lock In Profits And Minimize Losses
IBD's proprietary RS Rating measures technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the last 52 weeks compares to the rest of the market.
Decades of market research shows that the market's biggest winners tend to have an 80 or better RS Rating as they begin their largest climbs. See if Exact Sciences can continue to show renewed price strength and clear that threshold.
While now is not an ideal time to jump in, see if the stock goes on to establish and enter a buy zone in heavy trade.
Exact Sciences showed 0% EPS growth in the latest quarterly report. Revenue gains came in at 11%.
Exact Sciences holds the No. 78 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and ACADIA Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
